Analysis of Patent Layout of Small Nucleic Acid Drug Ligand Conjugate Delivery Technology

OBJECTIVE To provide a reference for the R&D strategic planning and patent strategy formulation of small nucleic acid drug R&D companies in China. METHODS Searched patents related to small nucleic acid drug ligand conjugation technology through PatSnap patent database, and obtained core patents and peripheral patents in this field through manual indexing. Firstly, analyzed the overall application trend of related patents, and secondly analyzed the core patents of the three types of small nucleic acid drug ligand conjugation technologies in detail. RESULTS & CONCLUSION On the whole, most of the core patents of small nucleic acid drug ligand conjugate delivery technology are in the hands of top international nucleic acid drug R&D companies such as Ionis, Alnylam, Arrowhead, and Arbutus, while the research capabilities and patent layout strength of domestic companies are relatively weak. Separately, the small nucleic acid drug ligand conjugated delivery technology mainly includes galactose derivative conjugated delivery technology, lipid derivative conjugated delivery technology, and cell penetrating peptide conjugated delivery technology. The most promising direction is the delivery technology of galactose derivatives conjugated. Lipid derivative conjugated delivery technology has received relatively low attention in recent years compared to galactose derivative conjugated delivery technology. Most of the patents have been deployed too early and most of them are in a state of failure. The cell penetrating peptide conjugated delivery technology has attracted more and more attention in recent years.